Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature
- 15 March 2019
- journal article
- review article
- Published by Springer Nature in Archives of orthopaedic and trauma surgery
- Vol. 139 (10) , 1339-1349
Abstract
Denosumab is a human monoclonal antibody (mAb) that specifically inhibits tumor-associated bone lysis through the RANKL pathway and has been used as neoadjuvant therapy for giant-cell tumor of bone (GCTB) in surgical as well as non-surgical cases. The purpose of this systematic review of the literature, therefore, is to investigate: (1) demographic characteristics of patients affected by GCTBs treated with denosumab and the clinical impact, as well as, possible complications associated with its use (2) oncological outcomes in terms of local recurrence rate (LRR) and development of lung metastasis, and (3) characteristics of its treatment effect in terms of clinical, radiological, and histological response.Keywords
This publication has 33 references indexed in Scilit:
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studyThe Lancet Oncology, 2013
- Giant Cell Tumor of Bone: Review, Mimics, and New Developments in TreatmentRadioGraphics, 2013
- Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of BoneClinical Cancer Research, 2012
- RANKL, denosumab, and giant cell tumor of boneCurrent Opinion in Oncology, 2012
- Giant Cell Tumor of Bone: Risk Factors for RecurrenceClinical Orthopaedics and Related Research, 2010
- Giant Cell Tumor of BoneAmerican Journal of Clinical Oncology, 2006
- Interferon therapy for vascular tumors of boneCurrent Orthopaedic Practice, 2001
- Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell TumorsJournal of Bone and Mineral Research, 2000
- Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases.American Journal of Roentgenology, 1992
- Publication bias in clinical researchThe Lancet, 1991